Phaarmasia Limited

BSE:523620 Stock Report

Market Cap: ₹330.7m

Phaarmasia Valuation

Is 523620 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 523620 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 523620 (₹48.44) is trading above our estimate of fair value (₹2.26)

Significantly Below Fair Value: 523620 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 523620?

Key metric: As 523620 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 523620. This is calculated by dividing 523620's market cap by their current revenue.
What is 523620's PS Ratio?
PS Ratio1.1x
Sales₹292.90m
Market Cap₹330.70m

Price to Sales Ratio vs Peers

How does 523620's PS Ratio compare to its peers?

The above table shows the PS ratio for 523620 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.2x
511523 Veerhealth Care
2.9xn/a₹402.4m
526345 Panjon
2.8xn/a₹428.7m
VILINBIO Vilin Bio Med
2.3xn/a₹304.1m
524606 Beryl Drugs
0.8xn/a₹169.6m
523620 Phaarmasia
1.1xn/a₹330.7m

Price-To-Sales vs Peers: 523620 is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does 523620's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?

13 CompaniesPrice / SalesEstimated GrowthMarket Cap
NECLIFE Nectar Lifesciences
0.4xn/aUS$86.45m
539561 Remedium Lifecare
0.07xn/aUS$27.40m
532637 Mangalam Drugs & Organics
0.5xn/aUS$20.09m
531173 Syschem (India)
0.5xn/aUS$18.34m
523620 1.1xIndustry Avg. 3.0xNo. of Companies19PS02.44.87.29.612+
13 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 523620 is good value based on its Price-To-Sales Ratio (1.1x) compared to the Indian Pharmaceuticals industry average (3x).

Price to Sales Ratio vs Fair Ratio

What is 523620's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

523620 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.1x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 523620's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

7D

0%

1Y

-45.9%

Sanofi India

₹142.5b

Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.

SANOFI

₹6,196.05

7D

0.8%

1Y

-22.8%

Colinz Laboratories

₹141.3m

Manufactures, markets, and trades in pharmaceutical formulations in India.

531210

₹56.10

7D

3.0%

1Y

37.2%